INmune Bio (INMB) vs Genenta Science S.p.A. (SAEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
INmune Bio is the larger company by market cap ($25.6 million vs $24.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INMB | SAEN |
|---|---|---|
| Share price | $0.827 | $0.5074 |
| Market cap | $25.60M | $24.47M |
| 1-day change | -7.50% | -9.39% |
| YTD return | -46.99% | — |
| 1-year return | -45.23% | — |
| 5-year return | -93.80% | — |
| EPS (TTM) | $-0.60 | $-0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $50.00K | — |
| Revenue growth (YoY) | +257.14% | — |
| Net income (latest FY) | $-45.93M | — |
| Operating margin | -94766.00% | — |
| Net margin | -91866.00% | — |
| 52-week high | $2.60 | $2.58 |
| 52-week low | $0.8189 | $0.50 |
| Distance from 52-week high | -68.19% | -80.33% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +746.43% | — |
| Average volume | 338.47K | 85.01K |
| Shares outstanding | 30.96M | 48.22M |
| Employees | 21 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Genenta Science S.p.A.
SAEN stock →Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 9 employees
INMB vs SAEN FAQ
Which is bigger, INmune Bio or Genenta Science S.p.A.?
INmune Bio (INMB) is larger, with a market capitalization of $25.60M compared with $24.47M for Genenta Science S.p.A. (SAEN).
Are INmune Bio and Genenta Science S.p.A. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.